Table 2.

BMD changes at the lumbar spine and total hip with associated 95% confidence intervals between baseline and 7 years according to strata and treatment allocation.

	Stratum I			Stratum II						Stratum III
	P (N = 206)	A (N = 205)	P value	P/P (N = 64)	P/R (N = 48)	P value	A/P (N = 53)	A/R (N = 60)	P value	P (N = 43)	A (N = 37)	P value
Lumbar spine	−1.37 (−2.16 to −0.57)	−3.94 (−4.71 to −3.17)	0.0007	0.32 (−0.97 to 1.60)	2.83 (0.92 to 4.74)	0.175	−2.37 (−3.97 to −0.77)	1.34 (−0.11 to .78)	0.0007	3.80 (1.70 to 5.90)	2.82 (0.91 to 4.74)	0.99
Total hip	−4.31 (−4.91 to −3.71)	−5.06 (−5.72 to −4.40)	20.7	−3.85 (−4.87 to −2.83)	−0.31 (−1.74 to 1.12)	0.0007	−3.66 (−5.02 to −2.31)	−2.44 (−3.76 to −1.12)	0.99	−0.17 (−1.61 to 1.27)	−0.86 (−2.74 to 1.03)	0.99

Women in stratum I had healthy BMD at baseline, those in stratum II were osteopenic, and those in stratum III were osteoporotic. P values are for a comparison between allocated treatment groups. P values are corrected for multiple comparisons.

A Anastrozole, P Placebo, R Risedronate.